Apply to trial NCT07459634

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening